Chemours has appointed Mary B. Cranston, former Chair and CEO of Pillsbury Winthrop Shaw Pittman LLC, as the new Chair of its Board of Directors. Cranston, who has been a director since 2015, led Chemours’ multi-year Board refresh, bringing in leaders aligned with the company’s strategic priorities. She brings decades of governance leadership experience from serving on boards of global public companies, including Visa, McAfee, and TPG. ([epicos.com](https://www.epicos.com/article/968866/chemours-announces-board-leadership-appointments-mary-cranston-named-chair-alister?utm_source=openai))
In her new role, Cranston will manage the Board, set the agenda, and drive its focus on strategy and shareholder value creation. She expressed her commitment to working closely with fellow directors to support the management team in executing Chemours’ “Pathway to Thrive” strategy. ([epicos.com](https://www.epicos.com/article/968866/chemours-announces-board-leadership-appointments-mary-cranston-named-chair-alister?utm_source=openai))
Alister Cowan, appointed to the Board in 2023, has been named Lead Independent Director. Cowan is a seasoned financial executive with over 30 years of experience, including 15 years as a public company CFO. He brings deep expertise in capital markets, risk management, and corporate development, having served as CFO of Suncor Energy and Husky Energy. ([epicos.com](https://www.epicos.com/article/968866/chemours-announces-board-leadership-appointments-mary-cranston-named-chair-alister?utm_source=openai))
These leadership appointments come as Chemours continues to focus on its strategic growth initiatives. The company’s stock is currently trading at $14.87, reflecting a slight decrease of 0.73% from the previous close.